Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease - Wikidata - awgldk - TriplyDB

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

http://www.wikidata.org/entity/Q24245141

about

Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease Long-acting beta2-agonists for chronic obstructive pulmonary disease Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease β(2) -adrenoceptor agonists: current and future direction Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review Informing evidence-based decision-making for patients with comorbidity: availability of necessary information in clinical trials for chronic diseases The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary Disease A cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications.An integrative review of systematic reviews related to the management of breathlessness in respiratory illnesses High prevalence of potential biases threatens the interpretation of trials in patients with chronic disease.Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications.Clinical predictors of frequent exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD)Disability related to COPD tool (DIRECT): towards an assessment of COPD-related disability in routine practice.Panax ginseng C.A Meyer root extract for moderate chronic obstructive pulmonary disease (COPD): study protocol for a randomised controlled trial Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD.Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.The safety and effectiveness of the current treatment regimen with or without roflumilast in advanced COPD patients: A systematic review and meta-analysis of randomized controlled trials.Role of arformoterol in the management of COPD Medication adherence issues in patients treated for COPD.Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD The Saudi Guidelines for the Diagnosis and Management of COPD.Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.The clinical and economic burden of chronic obstructive pulmonary disease in the USA.Rebuttal: should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? No.Should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? NO Réfutation: Faut-il éviter les β-agonistes dans les cas de bronchopneumopathies chroniques obstructives modérées et graves?: NON.Recommendations for the pharmacological treatment of COPD: questions and answers.Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.

P2860

Q24186411-C68F7C03-912A-40B2-9493-1419EB1FA475 Q24197467-8626D195-612E-4FEB-8E92-B523F5BF1433 Q24199130-B072815B-F6A0-4DED-8EF3-C4B12C462C33 Q24200331-E0F5C099-E2A5-466C-AF66-B01C8CD51255 Q24200446-C8CA8740-E4FA-4AF2-A83C-C9A7F5BD4358 Q24200476-ECDE5647-0BBD-43EB-8BAF-EA94BAF193CB Q24202744-A1E0E6EC-C6FD-4D0F-AC6E-26309AC10480 Q24234343-4FA87B49-C8A9-4077-B96E-F242C381D785 Q24243515-E5B9594D-1732-4983-A82B-E36B4DF0B3C9 Q24243564-2FF522F9-B378-4BD9-A99A-B075C6ACB5E6 Q24604047-47CE1484-C10F-4FA2-A79E-D98C6C8087E7 Q26782630-D1153A02-A88B-42BA-BDD8-9C80BFC43C6C Q27023214-90BF8997-38B7-4092-9104-75BCDD419248 Q28068078-AF0B8F4E-8406-4854-8B5D-CB1B6E512ED7 Q33736509-3BD2F776-E459-43F7-93B5-1FCFCA3972E1 Q33766956-81EB86E0-E4C8-49F6-96DA-F480DE1DFAF0 Q33929737-CFF35BC1-4AA2-4FCE-AD19-338EB3DD6937 Q34001895-83A3759F-2BEB-4666-803C-09922749ACEF Q34612842-06F1DDC8-4C0F-43D1-BA85-EE91DEDD8D74 Q35097000-CE854787-428A-4DAD-839F-FF3471C81607 Q35147449-F6FB7AEF-F64F-48AA-89DF-0A2DB6025E70 Q35170142-F2BD339C-08F6-4932-8470-EB24520A4927 Q35538249-A460C906-A981-420D-B990-D907AE15EB4C Q36983256-7DEAF164-979A-4C32-9287-6487BACE9FD4 Q37070335-59C6D002-CCD8-4A5B-9AB3-938EB8000A11 Q37070340-88E636BA-C30F-48F0-99E6-F5DBDFB937C6 Q37177278-1AE5F61A-5BD2-4A9E-82A5-06D95D223AED Q37181446-94E8284B-DBA5-40CF-ACA8-A218235F635E Q37614090-972F572D-C058-4C4B-BF3C-031555BA3E1B Q37733309-79EFA702-1549-4E01-9B0E-E650F96EE5C2 Q41282858-88CEB4DF-450E-443E-B73A-2D05406BFF82 Q41548699-3B3457B3-2122-48A2-AECF-5665B107571D Q41954093-D36C49CF-1C65-4C4D-892C-28ECE8504057 Q42414640-812F1473-ABCE-4CAA-B49E-06481C712B56 Q45762530-28A8702E-B6B9-4790-816D-D2D15B361B50 Q47272746-1C495326-0CD4-4124-8A18-763FD8B4DD1B Q55264356-73FA4AFD-15D8-45A2-A16C-B947E6277D56

P2860

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

http://www.wikidata.org/entity/Q24245141

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

@ast

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

@en

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

@en-gb

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

@nl

type

label

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

@ast

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

@en

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

@en-gb

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

@nl

prefLabel

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

@ast

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

@en

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

@en-gb

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

@nl

P1433

Q24245141-6BB68E6A-324A-4200-B76E-F15B7B2DA3B5

P1476

Q24245141-FCAB3C99-E42B-4CE0-BA03-8D480CBD134D

P2093

Q24245141-300682EB-4575-4F31-B78A-813F1997D0A7

Q24245141-55615BF5-C3AE-45B3-B60D-C0422E8A859C

Q24245141-A0C53792-9CCD-4A57-954A-71F4F06BA16E

Q24245141-CA259627-4B8D-4A41-8628-E56B1D99FA71

Q24245141-F49AEF37-5666-4CAA-A7FF-7B588F98B841

P2860

Q24245141-133EEB92-7284-4336-8641-4F4963F1AA27

Q24245141-15BCB5EC-D9B7-4AFD-BC0F-1BADC4E67C33

Q24245141-202D5143-36E3-4EF8-BA7B-172F428AB6EA

Q24245141-2354A2AB-DD1C-46A9-BC43-2A4356976A41

Q24245141-25B24641-10A6-4BA9-AB23-11B552F3941B

Q24245141-26B70A6B-8D00-4DD2-9681-4791B87AFBB5

Q24245141-2FACB521-A496-4F17-8CEB-059A99D9FE60

Q24245141-2FE3387E-2839-411A-AC45-7E2A24AD202D

Q24245141-34918D79-C501-4800-8A39-94CE0ABD76AF

Q24245141-36AB7B9D-D288-46F9-9FBD-CBA8279B15E0

P31

Q24245141-C92567F5-8D21-4968-9135-3E046D9D97E2

Q24245141-a8c6a4f0-b812-4161-9bf0-5acc12e14af6

P3181

Q24245141-3F1481B8-DA74-4C71-BBAC-E8DAA2B38ECE

P356

Q24245141-3D7FA0AC-D52F-44FF-9E4E-A16BF77FBBC0

P50

Q24245141-68B2566F-19A8-49BB-9DDE-FF5B9F5BFD5D

Q24245141-8044CC0D-2388-49FB-9533-F314EF022CBF

P577

Q24245141-EAC70397-8857-4AA3-9007-6C5A9AB13276

P698

Q24245141-E076D793-A43E-416A-81C5-825DD5BE2957

P921

Q24245141-A966D8D4-C3FD-40A3-A8FE-1774B93E78A2

P3181

P356

14651858.CD001104.PUB2

P1433

Cochrane Database of Systematic Reviews

P1476

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

@en

P2093

Antony Veale

http://www.w3.org/2001/XMLSchema#string

Brian J Smith

http://www.w3.org/2001/XMLSchema#string

Christopher J Cates

http://www.w3.org/2001/XMLSchema#string

Matthew Ming Ki Chan

http://www.w3.org/2001/XMLSchema#string

Toby J Lasserson

http://www.w3.org/2001/XMLSchema#string

P2860

Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma

Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease

Tiotropium for stable chronic obstructive pulmonary disease

Simpson's paradox and calculation of number needed to treat from meta-analysis

Measuring inconsistency in meta-analyses

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

Bronchodilator reversibility testing in chronic obstructive pulmonary disease

Impact of preventing exacerbations on deterioration of health status in COPD.

P31

scholarly article

P3181

3125349

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/14651858.CD001104.PUB2

http://www.w3.org/2001/XMLSchema#string

P50

Phillippa Poole

P577

2006-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16855959

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease